查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1848840

腸道疾病檢測市場按檢測方法、產品類型、最終用戶、病原體、檢體類型和分銷管道分類－全球預測，2025-2032年

Enteric Disease Testing Market by Test Method, Product Type, End User, Pathogen, Sample Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，腸道疾病檢測市場將成長至 70.5 億美元，複合年成長率為 5.64%。

關鍵市場統計數據
基準年 2024 45.4億美元
預計年份：2025年 48億美元
預測年份 2032 70.5億美元
複合年成長率 (%) 5.64%

全面了解不斷發展的腸道疾病檢測領域，其中技術、法規和臨床需求共同塑造了診斷策略。

腸道疾病檢測處於臨床緊迫性和技術創新交匯點，其驅動力在於快速檢測和應對細菌、病毒和寄生蟲爆發的迫切需求。診斷實驗室、醫院、研究機構和學術中心依賴日益多樣化的套件，包括生物化學檢驗、培養方法、免疫檢測、分子診斷和定序技術。同時，不斷發展的法律規範、不斷變化的醫保環境以及患者就醫路徑也在重塑檢測方法的驗證、應用和整合到常規工作流程中的方式。

當今的檢測生態系統兼顧了選擇性和非選擇性培養等傳統方法與即時聚合酵素鏈鎖反應）和次世代定序等現代技術。在這種混合環境中，實驗室管理者和臨床負責人必須權衡通量、靈敏度、週轉時間和擁有成本之間的優缺點。因此，採購決策不再是簡單地用一種技術取代另一種技術，而是更專注於建立互補的診斷路徑，以最佳化患者照護和監測能力。

此外，多重檢測、快速側向層析技術和數據分析軟體的普及，正在擴大腸道檢測的應用範圍。因此，各機構必須克服採購的複雜性、培訓需求和資料管理方面的挑戰，同時也要維持診斷品質並遵守認證標準。本文將探討一個科學嚴謹性與營運實用性結合的市場，以及策略選擇如何決定機構抵禦下一波腸道疾病威脅的能力。

技術融合和營運現代化將如何重塑診斷方式，並提升臨床和公共衛生領域的病原體檢測能力？

隨著技術的成熟、工作流程的整合以及人們對監測期望的不斷提高，腸道疾病檢測的模式正在改變。分子診斷正從小眾研究應用轉向第一線臨床工具，聚合酵素鏈鎖反應）變異、恒溫環型核酸擴增）和即時PCR能夠更快、更靈敏地檢測細菌、病毒和寄生蟲標靶。同時，包括次世代定序儀和桑格定序在內的定序平台正被整合用於病原體鑑定、疫情追蹤和抗菌藥物抗藥性分析，從而增強了數據分析和生物資訊學在常規臨床實踐中的作用。

同時，免疫檢測方法也日趨多樣化，化學化學冷光檢測法、酵素結合免疫吸附試驗和側向層析免疫分析等技術的出現，拓展了照護現場和實驗室檢測的選擇範圍。雖然培養仍然是分離株回收和藥敏試驗的關鍵步驟，但越來越多的實驗室正在將培養與快速分子檢測相結合，以加快病例管理。儀器自動化和整合耗材系統的興起減輕了人工操作負擔，軟體和維護服務也逐漸成為採購討論的核心內容。

這種技術變革也體現在營運和市場動態中。包括診斷實驗室、醫院、研究機構和學術中心在內的終端使用者正在調整工作流程，以適應多重檢測和高通量定序。分銷管道也在相應調整，直銷、分銷商和線上平台各自在滿足需求方面發揮不同的作用。這些變化正在重新定義公共衛生機構和臨床醫務人員檢測、報告和應對腸道威脅的方式。

評估2025年關稅調整如何重塑診斷相關人員的採購慣例、供應鏈彈性策略和資本規劃。

2025年關稅的實施和調整為腸道疾病檢測的採購和供應鏈規劃帶來了新的複雜性。影響進口耗材、儀器和某些檢測設備的關稅調整迫使製造商和經銷商重新評估籌資策略、調整定價模式並最佳化庫存緩衝，以維持檢測服務的連續性。這些措施對採購週期、資本投資計畫以及國產產品與進口產品的相對競爭力都產生了連鎖反應。

依賴專用試劑、套件和定序耗材的實驗室被迫尋找替代供應商或協商長期供應協議，以減輕成本波動的影響。儀器製造商則透過重新設計材料清單、盡可能實現部分生產流程本地化以及提升服務水準來應對新關稅環境下的整體擁有成本。此外，經銷商也拓展了物流路線並整合貨運，以更有效地控制到岸成本。

關稅也影響了終端用戶在進行資本投資時的策略考量。醫院和參考實驗室權衡了租賃和購買設備的利弊，一些機構為了避免短期成本上漲，在關稅生效前加快了採購速度。同時，軟體和維護服務領域的機構也開始著重挖掘現有資產的更多價值，而不是立即升級硬體。總體而言，關稅的累積影響凸顯了供應鏈韌性、供應商多元化和基於價值的採購在維持腸道檢測能力方面的重要性。

基於深度細分的洞察揭示了檢測方法、產品、最終用戶需求和病原體優先順序之間的交集，從而指導策略投資。

了解市場區隔動態對於使產品開發和上市策略與使用者需求保持一致至關重要，這涵蓋了檢測方法、產品類型、最終用戶、病原體、樣本類型和分銷管道等各個方面。檢測方法包括傳統的生化檢測（包括自動化和手動檢測）、培養技術（包括非選擇性和選擇性培養基）以及免疫檢測（例如化學冷光、酵素結合免疫吸附和側向流動免疫分析）。分子診斷透過恒溫環型核酸擴增、常規PCR和即時PCR平台提案明確的價值主張，而從Sanger測序到次世代定序等定序技術則支持對病原體進行深入的表徵和監測。

在產品方面，套件和試劑等耗材是日常運作的核心，而免疫分析儀、PCR儀和定序儀等儀器則是決定通量和產能的資本投資。與之配套的是軟體和服務，特別是數據分析工具和維護程序，它們能夠延長儀器的運作，並將原始輸出轉化為可執行的洞察。最終用戶涵蓋學術和臨床實驗室、診斷參考中心、醫院和研究機構，每個用戶都有各自的採購週期、監管要求和性能預期。

曲狀桿菌、大腸桿菌和沙門氏菌等細菌病原體需要培養和分子檢測雙重確認；腺病毒、諾羅病毒和輪狀病毒等病毒病原體則需要採用高靈敏度的分子檢測和免疫檢測；而寄生蟲則需要專門的樣本處理通訊協定。血液、直腸拭子和糞便等樣本類型對上游處理和核酸萃取都有不同的要求，這些都會影響檢測方法的選擇和工作流程的設計。此外，分銷管道（包括直銷、分銷商和線上平台）會影響前置作業時間、服務水準和客戶參與模式。將這些細分市場進行對比分析，可以揭示整合解決方案、捆綁式耗材和儀器服務以及針對性產品改進如何釋放臨床和營運價值。

區域間的差異化動態驅動診斷技術的差異化應用，影響採購路徑，並塑造供應鏈韌性策略。

區域動態對美洲、中東和非洲以及亞太地區的採用模式、監管路徑和供應鏈結構有顯著影響。在美洲，臨床實驗室和醫院系統通常優先考慮快速分子診斷和高通量設備，以應對大量患者和支持疫情爆發，而監管核准和報銷機制則決定新檢測方法的採用速度。該地區的實驗室網路也在投資測序能力以用於監測，這推動了對耗材和生物資訊解決方案的需求。

在中東和非洲地區，法規環境的多樣性和醫療基礎設施的差異化，為集中式參考實驗室和分散式檢查模式創造了不同的發展機會。在許多國家，嚴格的驗證要求凸顯了認證試劑和認可工作流程的重要性，而公共衛生優先事項則推動了對能夠整合多重檢測和監測數據的平台進行投資。分銷策略必須考慮到跨多個司法管轄區的複雜物流以及不同的採購慣例。

亞太地區擁有高度都市化的中心和快速發展的實驗室市場，這共同催生了對尖端定序和可擴展免疫檢測平台的需求。在一些國家，本地製造地影響供應鏈的韌性和成本結構，而與區域經銷商的合作則能加速市場進入。在整個亞太地區，公私合作舉措、跨境監測計畫和區域採購架構正日益影響腸道微生物組檢測資源的分配和部署方式。

市場參與企業如何透過整合產品、策略夥伴關係和以數據為中心的服務來實現差異化，從而獲得持續的臨床應用？

腸道檢測產業的龍頭企業正致力於開發整合儀器、耗材和數位化服務的整合解決方案，以提高客戶維繫和生命週期價值。擁有成熟免疫測量和分子生物學產品組合的公司正投資於自動化和互聯互通，以縮短週轉時間並提高結果的可重複性；而測序服務提供者則在推進文庫製備試劑套件和簡化生物資訊流程，以降低技術應用門檻。規模較小的創新企業則專注於快速照護現場橫向流動化驗、等溫擴增試劑套件以及針對難培養標靶的專用培養基等細分領域。

策略活動包括透過夥伴關係拓展通路、共同開發契約加速檢測方法檢驗，以及加強售後服務以提高設備運作和客戶滿意度。一些公司正專注於採用混合市場推廣模式，將直接交易與通路夥伴關係結合，以滿足日益多元化的終端用戶偏好。我們還觀察到一種新興趨勢，即基於訂閱和服務的產品模式，將耗材與儀器和軟體捆綁銷售，從而簡化收入來源並加深客戶關係。

競爭優勢日益取決於數據能力，包括與實驗室資訊系統的互通性、強大的數據分析軟體以及將複雜的測序結果轉化為臨床相關資訊的服務。隨著相關人員將快速診斷、擴充性和可操作性洞察置於優先地位，能夠提供端到端解決方案並展現可衡量營運效益的公司更有可能獲得更強大的市場地位。

製造商和醫療系統可以採取哪些策略行動來增強韌性、加速產品推廣應用並獲得可衡量的營運和臨床效益

產業領導者應採取果斷行動，加強供應鏈建設，加速數位整合，並使產品系列與終端用戶的實際工作流程相契合。首先，供應商多元化和建立緊急庫存策略可以降低貿易中斷和關稅波動帶來的風險。其次，投資於儀器、實驗室資訊系統和分析平台之間的無縫數據連接，將提高營運效率，並增強高成本儀器的價值提案。

第三，製造商和經銷商應考慮採用模組化商業模式，將耗材、儀器和軟體服務整合到訂閱計畫中。這種模式可以降低資源有限的實驗室的進入門檻，同時提供可預測的收入來源。第四，優先開發兼顧靈敏度、週轉時間和易用性的檢測方法，特別是針對常見腸道病原體（如曲狀桿菌、大腸桿菌、沙門氏菌、諾羅病毒和輪狀病毒）的檢測方法，可以滿足臨床和公共衛生需求。第五，有針對性地投資於培訓、技術支援和維護服務，可以確保設備運作並提高客戶滿意度，尤其是在檢測能力參差不齊的地區。

最後，加強與學術中心、公共衛生機構和醫院網路的合作，將有助於共同開發和檢驗以監測為重點的解決方案。透過實施這些措施，產業領導者可以增強韌性，加速創新診斷技術的應用，並在臨床和實驗室環境中帶來可衡量的效益。

嚴謹的混合方法研究框架，整合了相關人員訪談、技術文獻綜述和跨來源三角驗證，以確保獲得可靠的見解。

本分析採用的調查方法結合了定性和定量方法，旨在全面了解腸道疾病檢測的動態變化。主要研究包括對實驗室主任、臨床微生物學家、採購人員和產品經理進行結構化訪談，以了解實際營運中的限制因素、推廣應用的促進因素和技術偏好。此外，還與分銷合作夥伴和服務機構進行了補充討論，以了解物流、價格壓力和售後服務支援模式等方面的背景資訊。

次要研究包括對監管指南、臨床實踐標準和近期同行評審文獻的系統性回顧，以確認其與檢驗的測試程序和預期診斷效能的一致性。此外，還分析了產品文獻、製造商技術規格和設備維修手冊，以評估其吞吐量特性、耗材依賴性和整合能力。透過對不同測試方法、產品類型和最終用戶類型的比較分析，識別出反覆出現的主題、能力差距和商業化路徑。

數據綜合分析強調資訊來源的三角驗證，以協調不同相關人員的觀點並減少偏見。在整個過程中，我們關注可重複性、資料來源的透明度以及研究結果對臨床實驗室、醫院、研究機構和學術中心的相關性。這種混合方法既能提供可靠且可操作的見解，又能充分考慮腸道疾病檢測中存在的操作異質性。

整合技術、營運和策略主題，重點闡述如何實現快速、可靠的腸道疾病診斷，以滿足臨床和公共衛生需求。

腸道疾病檢測領域的特點是技術快速發展、操作複雜以及市場壓力不斷變化，這些因素共同要求相關人員制定清晰的策略。傳統方法在病原體分離和抗藥性分析中仍然發揮關鍵作用，而分子和定序技術已成為及時檢測和流行病學調查的必要手段。耗材、儀器、軟體和服務如今構成了一個相互依存的生態系統，其中一個領域的決策會影響其他領域的績效和價值實現。

區域差異、關稅主導的採購調整以及對穩健分銷策略的需求，凸顯了靈活的商業模式和強大的售後服務能力的重要性。從集中式參考實驗室到即時偵測點，終端使用者需要量身訂製的解決方案，這些方案需考慮樣本類型、目標病原體和通量需求。能夠提供整合式、數據驅動型解決方案並投資於夥伴關係和本地支援體系的公司，將更有能力滿足這些多樣化的需求。

展望未來，該行業的發展軌跡將受到檢測化學、自動化和生物資訊學領域持續創新以及構建供應鏈韌性和監管一致性的共同努力的影響，從而形成更快速的診斷基礎設施，更好地支持臨床決策和腸道疾病的公共衛生監測。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴展多重分子檢測範圍，同時檢測多種腸道病原體，可縮短診斷時間
  • 採用快速照護現場免疫檢測進行以地區為基礎諾羅病毒和輪狀病毒感染疾病檢測
  • 將次世代定序整合到臨床環境中，以實現全面的疫情源頭追蹤和抗菌素抗藥性分析
  • 推出基於 CRISPR 技術的糞便樣本中微量腸道病原體超靈敏檢測診斷平台
  • 診斷設備製造商與遠端醫療提供者建立策略夥伴關係，以促進遠距會診和諮詢。
  • 在公共衛生監測中，將數位化糞便診斷與人工智慧分析相結合，用於腸道疾病爆發的預測建模。
  • 用於可攜式多重檢測細菌、病毒和寄生蟲腸道病原體的實驗室晶片設備的監管核准和商業化
  • 糞便微生物組檢測作為胃腸道感染疾病鑑別診斷和個人化治療的輔助工具，需求日益成長

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依檢測方法分類的腸道疾病檢測市場

  • 生物化學檢驗
    • 自動生化分析
    • 手動生物化學檢驗
  • 培養方法
    • 非選擇性培養
    • 選擇性培養
  • 免疫檢測
    • 化學冷光免疫檢測
    • 酵素結合免疫吸附試驗
    • 橫向流動化驗
  • 分子診斷
    • 環介導等溫擴增
    • 聚合酵素鏈鎖反應
    • 即時聚合酵素鏈鎖反應
  • 定序
    • 次世代定序
    • 桑格定序

9. 腸道疾病檢測市場（依產品類型分類）

  • 消耗品
    • 套件
    • 試劑
  • 儀器
    • 免疫分析儀
    • 聚合酵素鏈鎖反應裝置
    • 序列器
  • 軟體和服務
    • 數據分析軟體
    • 維護服務

第10章 依最終用戶分類的腸道疾病檢測市場

  • 學術和臨床研究實驗室
  • 診斷實驗室
  • 醫院
  • 研究所

11. 按病原體分類的腸道疾病檢測市場

  • 細菌病原體
    • 曲狀桿菌
    • 大腸桿菌
    • 沙門氏菌
  • 寄生病原體
  • 病毒病原體
    • 腺病毒
    • 諾羅病毒
    • 輪狀病毒

第12章 依檢體類型分類的腸道疾病檢測市場

  • 血液檢體
  • 直腸拭子
  • 糞便檢體

13. 腸道疾病檢測市場（依通路分類）

  • 直銷
  • 經銷商
  • 線上銷售

14. 各地區腸道疾病檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 腸道疾病檢測市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國腸道疾病檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • Abbott Laboratories
    • Roche Holding AG
    • QIAGEN NV
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • Danaher Corporation
    • PerkinElmer, Inc.
    • DiaSorin SpA
Product Code: MRR-732E7CFCB4A5

The Enteric Disease Testing Market is projected to grow by USD 7.05 billion at a CAGR of 5.64% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.54 billion
Estimated Year [2025] USD 4.80 billion
Forecast Year [2032] USD 7.05 billion
CAGR (%) 5.64%

A comprehensive orientation to the evolving enteric disease testing environment where technology, regulation, and clinical needs converge to shape diagnostic strategy

Enteric disease testing sits at the intersection of clinical urgency and technological innovation, driven by the need to rapidly detect and respond to bacterial, viral, and parasitic outbreaks. Diagnostic laboratories, hospitals, research institutes, and academic centers rely on an increasingly diverse toolkit that includes biochemical testing, culture-based approaches, immunoassays, molecular diagnostics, and sequencing technologies. In parallel, evolving regulatory frameworks, changing reimbursement environments, and shifting patient pathways are reshaping how assays are validated, adopted, and integrated into routine workflows.

Today's testing ecosystem balances legacy methods such as selective and non-selective culture with modern modalities like real-time polymerase chain reaction and next-generation sequencing. This hybrid landscape requires laboratory managers and clinical leaders to evaluate trade-offs between throughput, sensitivity, turnaround time, and cost of ownership. As a result, purchasing decisions are less about replacing one technology with another and more about creating complementary diagnostic pathways that optimize patient care and surveillance capabilities.

Moreover, the proliferation of multiplex assays, rapid lateral flow formats, and data analysis software is expanding the operational footprint of enteric testing. Consequently, organizations must navigate procurement complexity, training needs, and data management challenges while preserving diagnostic quality and complying with accreditation standards. This introduction frames a marketplace where scientific rigor meets operational pragmatism, and where strategic choices will determine resilience against the next wave of enteric threats.

How technological convergence and operational modernization are redrawing diagnostic pathways and strengthening pathogen detection across clinical and public health settings

The landscape of enteric disease testing is undergoing transformative shifts driven by technological maturation, workflow consolidation, and heightened surveillance expectations. Molecular diagnostics have transitioned from niche research applications to frontline clinical tools, with polymerase chain reaction variants, loop mediated isothermal amplification, and real-time PCR enabling faster, more sensitive detection of bacterial, viral, and parasitic targets. At the same time, sequencing platforms, including next-generation and Sanger approaches, are being integrated for pathogen characterization, outbreak tracing, and antimicrobial resistance profiling, which elevates the role of data analytics and bioinformatics in routine practice.

Concurrently, immunoassays have diversified, as chemiluminescence assays, enzyme linked immunosorbent formats, and lateral flow devices expand point-of-care and laboratory-based testing options. Culture methods remain indispensable for isolate recovery and susceptibility testing, but laboratories increasingly combine culture with rapid molecular confirmation to accelerate case management. The rise of instrument automation and integrated consumable systems is reducing manual workloads, while software and maintenance services are becoming core components of procurement conversations.

These technological shifts are mirrored by operational and market dynamics. End users such as diagnostic laboratories, hospitals, research entities, and academic centers are reconfiguring workflows to accommodate multiplex testing and high-throughput sequencing. Distribution channels are adapting accordingly, with direct sales, distributors, and online platforms each playing distinct roles in meeting demand. Together, these changes are redefining how public health agencies and clinical providers detect, report, and respond to enteric threats.

Assessment of how tariff shifts in 2025 reshaped procurement practices, supply chain resilience strategies, and capital planning across diagnostic stakeholders

The introduction and adjustment of tariffs in 2025 have added a new layer of complexity to procurement and supply chain planning for enteric disease testing. Tariff adjustments affecting imported consumables, instruments, and certain laboratory components have compelled manufacturers and distributors to reassess sourcing strategies, adjust pricing models, and optimize inventory buffers to preserve continuity of testing services. These measures have had ripple effects across procurement cycles, capital expenditure planning, and the relative competitiveness of domestically produced versus imported goods.

Laboratories reliant on specialized reagents, kits, and sequencing consumables experienced pressure to identify alternative vendors or to negotiate long-term supply agreements that mitigate exposure to cost fluctuations. Instrument manufacturers responded by reengineering bills of materials, localizing certain production steps where feasible, and enhancing service offerings to justify total cost of ownership under new tariff environments. Furthermore, distributors diversified logistics routes and consolidated shipments to manage landed costs more effectively.

The tariffs also influenced the strategic calculus for end users considering capital investments. Hospitals and reference labs evaluated the trade-offs between leasing and purchasing equipment, and some accelerated procurement ahead of tariff implementations to avoid near-term cost increases. In parallel, software and maintenance services became more prominent as organizations sought to extract additional value from existing assets rather than pursue immediate hardware upgrades. Overall, the cumulative impact of tariffs has reinforced the importance of supply chain resilience, vendor diversification, and value-based procurement in sustaining enteric testing capabilities.

Deep segmentation-driven insights revealing where test method, product offerings, end-user needs, and pathogen priorities intersect to guide strategic investments

Understanding segmentation dynamics is essential to match product development and go-to-market strategies with user needs across test method, product type, end user, pathogen focus, sample type, and distribution channels. Test method considerations range from traditional biochemical tests with automated and manual approaches to culture techniques encompassing non-selective and selective media, as well as immunoassays spanning chemiluminescence, enzyme linked immunosorbent, and lateral flow formats. Molecular diagnostics present distinct value propositions through loop mediated isothermal amplification, conventional PCR, and real-time PCR platforms, while sequencing options from Sanger to next-generation sequencing support in-depth pathogen characterization and surveillance.

On the product side, consumables such as kits and reagents are core to day-to-day operations, whereas instruments including immuno analyzers, PCR machines, and sequencers represent capital investments that define throughput and capability. Complementing these are software and services, particularly data analysis tools and maintenance programs, which extend instrument uptime and translate raw outputs into actionable insights. End users span academic and clinical laboratories, diagnostic reference centers, hospitals, and research institutes, each with differing procurement cycles, regulatory requirements, and performance expectations.

Pathogen-specific segmentation underscores distinct assay design and clinical priorities: bacterial pathogens like Campylobacter, Escherichia coli, and Salmonella require both culture and molecular confirmation; viral targets such as adenovirus, norovirus, and rotavirus shift emphasis toward sensitive molecular and immunoassay detection; parasitic organisms demand specialized sample processing protocols. Sample types including blood, rectal swabs, and stool each impose upstream handling and nucleic acid extraction considerations that influence assay selection and workflow design. Finally, distribution channels-direct sales, distributors, and online platforms-shape lead times, service levels, and customer engagement models. Mapping these segments against one another reveals where integrated solutions, bundled consumable-instrument-service offerings, and targeted product enhancements can unlock clinical and operational value.

Comparative regional dynamics that drive differentiated adoption of diagnostics, influence procurement pathways, and shape supply chain resilience strategies

Regional dynamics materially influence adoption patterns, regulatory pathways, and supply chain configurations across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, clinical laboratories and hospital systems often prioritize rapid molecular diagnostics and high-throughput instruments to manage large patient volumes and support outbreak response, while regulatory approvals and reimbursement mechanisms shape the cadence of new test introductions. Laboratory networks in this region also invest in sequencing capabilities for surveillance, which drives demand for consumables and bioinformatics solutions.

Across Europe Middle East & Africa, diverse regulatory environments and heterogeneous healthcare infrastructures create differentiated opportunities for both centralized reference laboratories and decentralized testing models. In many countries, stringent validation requirements underscore the importance of certified reagents and accredited workflows, whereas public health priorities steer investment toward multiplex assays and platforms capable of integrating surveillance data. Distribution strategies must account for complex logistics across multiple jurisdictions and varying procurement practices.

The Asia-Pacific region presents a mix of highly advanced urban centers and rapidly developing laboratory markets, leading to simultaneous demand for cutting-edge sequencing and scalable immunoassay platforms. Local manufacturing hubs in some countries influence supply chain resilience and cost structures, and partnerships with regional distributors can accelerate market access. In all regions, collaborative public-private initiatives, cross-border surveillance programs, and regional procurement frameworks increasingly shape how enteric testing resources are allocated and deployed.

How market participants are differentiating through integrated offerings, strategic partnerships, and data-centric services to capture sustained clinical adoption

Major players across the enteric testing landscape are focusing on integrated solutions that combine instruments, consumables, and digital services to enhance customer retention and lifecycle value. Companies with established immunoassay and molecular portfolios are investing in automation and connectivity to reduce hands-on time and improve result reproducibility, while sequencing providers are advancing library preparation kits and streamlined bioinformatics pipelines to lower technical barriers for adoption. Smaller innovators are concentrating on niche areas such as rapid point-of-care lateral flow assays, isothermal amplification kits, or specialized media for challenging culture targets.

Strategic activity includes partnerships to expand distribution footprints, co-development agreements to accelerate assay validation, and after-sales service enhancements to improve uptime and customer satisfaction. Several firms emphasize hybrid go-to-market models that blend direct engagement with channel partnerships to address heterogeneous end-user preferences. There is also a clear trend toward subscription and service-based offerings that bundle consumables with instruments and software, thereby smoothing revenue streams and deepening customer relationships.

Competitive differentiation increasingly hinges on data capabilities, including interoperability with laboratory information systems, robust data analysis software, and services that translate complex sequencing outputs into clinically relevant intelligence. As stakeholders prioritize rapid diagnostics, scalability, and actionable insights, companies that can deliver end-to-end solutions and demonstrate measurable operational benefits will secure stronger positions in the market.

Actionable strategic moves for manufacturers and health systems to bolster resilience, accelerate adoption, and deliver measurable operational and clinical benefits

Industry leaders should act decisively to strengthen supply chains, accelerate digital integration, and align product portfolios with end-user workflow realities. First, diversifying supplier bases and establishing contingency inventory strategies will mitigate exposure to trade disruptions and tariff volatility. Second, investing in seamless data connectivity between instruments, laboratory information systems, and analytics platforms will unlock operational efficiencies and enhance the value proposition of higher-cost instrumentation.

Third, manufacturers and distributors should consider modular commercial models that combine consumables, instruments, and software services into subscription plans, which can lower barriers to entry for resource-constrained laboratories while providing predictable revenue streams. Fourth, prioritizing assay development that balances sensitivity, turnaround time, and ease of use-especially for common enteric pathogens like Campylobacter, Escherichia coli, Salmonella, norovirus, and rotavirus-will meet both clinical and public health needs. Fifth, targeted investments in training, technical support, and maintenance services will preserve uptime and improve customer satisfaction, particularly in regions with varied laboratory capabilities.

Finally, fostering collaborative relationships with academic centers, public health agencies, and hospital networks will enable co-development of surveillance-focused solutions and validation studies. By implementing these actions, industry leaders can enhance resilience, accelerate adoption of transformative diagnostics, and deliver measurable benefits across clinical and laboratory settings.

A rigorous mixed-methods research framework integrating stakeholder interviews, technical literature review, and cross-source triangulation to ensure credible insights

The research methodology underpinning this analysis combined qualitative and quantitative approaches to gather a comprehensive view of enteric disease testing dynamics. Primary engagements included structured interviews with laboratory directors, clinical microbiologists, procurement professionals, and product managers to capture real-world operational constraints, adoption drivers, and technology preferences. Supplementary discussions with distribution partners and service organizations provided context on logistics, pricing pressures, and after-sales support models.

Secondary research involved a systematic review of regulatory guidance, clinical practice standards, and recent peer-reviewed literature to ensure alignment with validated laboratory procedures and diagnostic performance expectations. Product literature, manufacturer technical specifications, and instrument service manuals were analyzed to evaluate throughput characteristics, consumable dependencies, and integration capabilities. Comparative analysis across test methods, product categories, and end-user types enabled identification of recurring themes, capability gaps, and commercialization pathways.

Data synthesis emphasized triangulation across sources to reconcile differing stakeholder perspectives and mitigate bias. Throughout the process, attention was paid to reproducibility, transparency in data sourcing, and the contextual relevance of findings to clinical laboratories, hospitals, research institutes, and academic centers. This mixed-methods approach supports robust, actionable insights while acknowledging the operational heterogeneity that characterizes enteric disease testing.

A synthesis of technological, operational, and strategic themes highlighting the path to resilient and responsive enteric diagnostics for clinical and public health needs

The enteric disease testing domain is characterized by rapid technological progress, operational complexity, and evolving market pressures that together demand strategic clarity from stakeholders. Traditional methods continue to play a vital role in pathogen recovery and resistance profiling, while molecular and sequencing technologies have become indispensable for timely detection and epidemiologic investigation. Consumables, instruments, software, and services now form an interdependent ecosystem where decisions in one area influence performance and value realization across others.

Regional nuances, tariff-driven procurement adjustments, and the need for resilient distribution strategies underscore the importance of flexible commercial models and strong after-sales capabilities. End users-from centralized reference laboratories to point-of-care settings-require tailored solutions that account for sample types, pathogen targets, and throughput needs. Companies that offer integrated, data-enabled solutions and that invest in partnerships and local support structures will be best positioned to meet these diverse requirements.

Looking ahead, the sector's trajectory will be shaped by continued innovation in assay chemistry, automation, and bioinformatics, alongside concerted efforts to build supply chain resilience and regulatory alignment. The cumulative effect will be a more responsive diagnostic infrastructure that better supports clinical decision-making and public health surveillance for enteric diseases.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of multiplexed molecular panels for simultaneous detection of multiple enteric pathogens reducing diagnosis time
  • 5.2. Adoption of rapid point of care immunoassays for community based detection of norovirus and rotavirus infections
  • 5.3. Integration of next generation sequencing in clinical settings for comprehensive outbreak source tracking and antimicrobial resistance profiling
  • 5.4. Deployment of CRISPR based diagnostic platforms for ultra sensitive detection of low abundance enteric pathogens in stool samples
  • 5.5. Strategic partnerships between diagnostic manufacturers and telehealth providers to facilitate remote enteric disease testing and consultation
  • 5.6. Implementation of digital stool diagnostics coupled with AI analytics for predictive modeling of enteric disease outbreaks in public health surveillance
  • 5.7. Regulatory approval and commercialization of lab on a chip devices for portable multiplexed detection of bacterial viral and parasitic enteric agents
  • 5.8. Rising demand for fecal microbiome testing as a complementary tool for differential diagnosis and personalized treatment of gastrointestinal infections

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Enteric Disease Testing Market, by Test Method

  • 8.1. Biochemical Tests
    • 8.1.1. Automated Biochemical Analysis
    • 8.1.2. Manual Biochemical Tests
  • 8.2. Culture Methods
    • 8.2.1. Non Selective Culture
    • 8.2.2. Selective Culture
  • 8.3. Immunoassays
    • 8.3.1. Chemiluminescence Immunoassay
    • 8.3.2. Enzyme Linked Immunosorbent Assay
    • 8.3.3. Lateral Flow Assay
  • 8.4. Molecular Diagnostics
    • 8.4.1. Loop Mediated Isothermal Amplification
    • 8.4.2. Polymerase Chain Reaction
    • 8.4.3. Real Time Polymerase Chain Reaction
  • 8.5. Sequencing
    • 8.5.1. Next Generation Sequencing
    • 8.5.2. Sanger Sequencing

9. Enteric Disease Testing Market, by Product Type

  • 9.1. Consumables
    • 9.1.1. Kits
    • 9.1.2. Reagents
  • 9.2. Instruments
    • 9.2.1. Immuno Analyzers
    • 9.2.2. Polymerase Chain Reaction Instruments
    • 9.2.3. Sequencers
  • 9.3. Software & Services
    • 9.3.1. Data Analysis Software
    • 9.3.2. Maintenance Services

10. Enteric Disease Testing Market, by End User

  • 10.1. Academic And Clinical Laboratories
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
  • 10.4. Research Institutes

11. Enteric Disease Testing Market, by Pathogen

  • 11.1. Bacterial Pathogens
    • 11.1.1. Campylobacter
    • 11.1.2. Escherichia Coli
    • 11.1.3. Salmonella
  • 11.2. Parasitic Pathogens
  • 11.3. Viral Pathogens
    • 11.3.1. Adenovirus
    • 11.3.2. Norovirus
    • 11.3.3. Rotavirus

12. Enteric Disease Testing Market, by Sample Type

  • 12.1. Blood Samples
  • 12.2. Rectal Swabs
  • 12.3. Stool Samples

13. Enteric Disease Testing Market, by Distribution Channel

  • 13.1. Direct Sales
  • 13.2. Distributors
  • 13.3. Online Sales

14. Enteric Disease Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Enteric Disease Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Enteric Disease Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Thermo Fisher Scientific Inc.
    • 17.3.2. bioMerieux SA
    • 17.3.3. Abbott Laboratories
    • 17.3.4. Roche Holding AG
    • 17.3.5. QIAGEN N.V.
    • 17.3.6. Becton, Dickinson and Company
    • 17.3.7. Bio-Rad Laboratories, Inc.
    • 17.3.8. Danaher Corporation
    • 17.3.9. PerkinElmer, Inc.
    • 17.3.10. DiaSorin S.p.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. ENTERIC DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. ENTERIC DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ENTERIC DISEASE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MANUAL BIOCHEMICAL TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MANUAL BIOCHEMICAL TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MANUAL BIOCHEMICAL TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MANUAL BIOCHEMICAL TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MANUAL BIOCHEMICAL TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MANUAL BIOCHEMICAL TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NON SELECTIVE CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NON SELECTIVE CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NON SELECTIVE CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NON SELECTIVE CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NON SELECTIVE CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NON SELECTIVE CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SELECTIVE CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SELECTIVE CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SELECTIVE CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SELECTIVE CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SELECTIVE CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SELECTIVE CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNO ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNO ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNO ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNO ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNO ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNO ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ACADEMIC AND CLINICAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ACADEMIC AND CLINICAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ACADEMIC AND CLINICAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ACADEMIC AND CLINICAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ACADEMIC AND CLINICAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ACADEMIC AND CLINICAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CAMPYLOBACTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CAMPYLOBACTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CAMPYLOBACTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CAMPYLOBACTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CAMPYLOBACTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CAMPYLOBACTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ESCHERICHIA COLI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ESCHERICHIA COLI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ESCHERICHIA COLI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ESCHERICHIA COLI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SALMONELLA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SALMONELLA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SALMONELLA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SALMONELLA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SALMONELLA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SALMONELLA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PARASITIC PATHOGENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PARASITIC PATHOGENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PARASITIC PATHOGENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PARASITIC PATHOGENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PARASITIC PATHOGENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PARASITIC PATHOGENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ADENOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NOROVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NOROVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NOROVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NOROVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NOROVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NOROVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ROTAVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ROTAVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ROTAVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ROTAVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ROTAVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BLOOD SAMPLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BLOOD SAMPLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BLOOD SAMPLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BLOOD SAMPLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RECTAL SWABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RECTAL SWABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RECTAL SWABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RECTAL SWABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RECTAL SWABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RECTAL SWABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY STOOL SAMPLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY STOOL SAMPLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY STOOL SAMPLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY STOOL SAMPLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY STOOL SAMPLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY STOOL SAMPLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)

TABLE